SUMMARY -Th e aim of the study was to assess the role of the estradiol and progesterone relationship during the late luteal phase and the occurrence of fi brocystic breast disease (FBD). Th e concentration of estradiol/progesterone was measured in the group of women with FBD as study group (n=50) and control group of women without FBD (n=40). All women had regular ovulation cycles. Blood samples for estradiol (E2), progesterone (P) and prolactin determination were obtained in the morning at 8 am on days 21 and 24 of menstrual cycle. Signifi cant mastalgia and mastodynia history in women with FBD was obtained with yes or no questionnaire. FBD diagnosis was confi rmed with ultrasound (size and number of simple cysts). In the control group, a reduced E2/P ratio was noticed from day 21 to day 24 of the cycle (from 14.8±11.5 pg/mL to 9.1±6.1 pg/mL; p<0.05), which was not recorded in the group of women with FBD (study group). Even the slightest disturbance of the E2/P ratio may contribute to the occurrence of FBD with clinical manifestations of mastalgia and mastodynia.
Introduction
Fibrocystic breast disease (FBD), recently called fi brocystic changes in the literature, is the most frequent benign breast disease, which is diagnosed in 50% of the clinically and 90% of the histopathologically examined women 1 . Its highest incidence is between 20 and 50 years of age, when a woman is most exposed to stress periods, e.g., her development in the society, forming a family and giving birth. In this period, her body is exposed to quite signifi cant hormone turbulences [2] [3] [4] .
Th e question is what causes the high incidence of these changes and how to ease the discomfort. Th e treatment is still just empirical, which leads the scientists to search for the pathophysiological cause of the changes and estimate the malignant potential. It is noted that, even in women with healthy hygienic-diet regimen and no risk habits such as excessive consumption of coff ee, opiates and smoking, the disease is still manifested.
Many researchers believe that changes in hormone status of prolactin, thyroid hormones and steroid ovary hormones may lead to development of benign changes in the breasts 4 . Although some studies show how the prevalence of increased estrogen concentration during the menstrual cycle (MC) could be one of the main pathophysiological disorders 5 , there are controversies found in the literature. Th ese controversies emphasize the absence of negative correlation between steroid ovary hormones and the occurrence of benign diseases of the breasts 6, 7 . So far, very few studies monitored the relation of sexual ovary hormones in the late luteal phase, most often in the fi rst 7 days after ovulation.
Regarding the incidence, suff ering and fear caused by benign changes in the breasts, studying secretion of just these hormones in the late MC secretion phase seemed to be quite important. Th e study was aimed at assessing the correlation between the hormones and the disease, in order to alleviate discomfort with appropriate therapy and improve emotional stability of the woman.
Patients and Methods
Th e study was conducted at the Department of Endocrinology, Clinical Center Serbia, and included 90 women with regular MC, aged 20 to 40 years, with normal body mass index (BMI) and waist/hip (W/H) ratio. Experimental group included 50 women with respective history data and clinical fi ndings, existence of mastalgia and mastodynia, and premenstrual syndrome (PMS). Ultrasound (US) examination showed simple cysts sized <1 cm in both breasts. Control group consisted of 40 healthy women without discomforts and PMS, and with regular clinical and US fi ndings of the breasts.
At the beginning of the MC follicular phase, all women underwent hormone status testing on empty stomach for thyroid hormones, gonadotropic hormones, prolactin (PRL), ovarian steroid hormones and adrenal gland, insulin and biochemical analyses (glucose, urea, creatinine, cholesterol, triglycerides, liver transaminases, plasma iontophoresis). During the MC luteal phase, on days 21 and 24, blood samples were obtained from both groups of subjects for estrogen (E2), progesterone (P) and prolactin (PRL) determination. Hormone analysis was performed on a Roche immunoassay analyzer (modular analytics E170) by electrochemiluminescence using the immunoassay method (ECLIA). Th e Elecsys 2010 immunoassay, reagent kit 03000079122 was used for estrogen, Elecsys 2010 immunoassay, reagent kit 12145383122 for progesterone and Elecsys 2010 immunoassay, reagent kit 0320309319 for prolactin measurement.
Linear multifunction large resolution linear probe 4.2-12 MHz, 38 mm, on a Loqic 5 GE device was employed for breast US examination. Th e study excluded pregnant women and those with any kind of malignant disease, endocrinopathy, complex dysplastic cysts, fi broadenoma, as well as those who were using or had used birth control therapy.
History data were obtained by use of questionnaires with yes/no answers on MC regularity, PMS, giving birth and number of births, existence of discomfort in the breasts in the previous six months (tension, pain, discharge, nodularity), use of birth control therapy, FBD in the family, consumption of coff ee and cigarettes, as well as healthy hygienic-diet regimen.
Th e study was conducted according to ethical principles and was approved by the Ethics Committee of the School of Medicine, University of Belgrade (no. 29/XI-8, 2012).
Results
Estrogen concentration measured on day 21 was not statistically diff erent between the two groups (p=0.7999). Within the control group, there was a statistically signifi cant drop of E2 from day 21 to day 24 (from 157.58±79.39 pg/mL to 124.89±52.34 pg/mL; p=0.010) (Fig. 1) .
Progesterone concentration on day 21 of the cycle was not statistically signifi cantly diff erent between the two groups of women (p=0.116), which confi rmed the Progesterone concentration within the control group was higher on day 24 relative to day 21 (from 13.79±8.66 ng/mL to 10.36±6.92 ng/mL; p<0.001) (Fig. 2) .
In control group, the E2/P ratio on day 24 was 9.1±6.1, which was a signifi cant decrease from day 21, when it was 14.8±11.1, whereas in the group of FBD women it increased signifi cantly from day 21 to day 24 of the cycle (from 12.1±10.7:18.9±23.8) (Fig. 3) . In FBD women, the level of estrogen and progesterone defi ciency in plasma on day 24 of MC caused a statistically signifi cant incidence of tension and pain (p<0.05) (Fig. 4) .
Tension and pain in the breasts were recorded in two women from the control group, however, it was of no statistical signifi cance.
Discussion
Fibrocystic breast disease is the most common breast disease in gynecologic and radio-oncologic practice. Th e most often manifested discomforts are pain and tension in the breasts and tender nodes palpable in the breasts. Th e discomfort causes fear in women and interferes with their daily activities. Th e increasing incidence of this disease may be infl uenced by age, obesity, smoking, hormone preparations, PMS, stress, ductectasia, and alcohol and caff eine consumption 8 . However, in the absence of the abovementioned potential risk factors, the question is what other risk factors may infl uence the pathophysiological process of this disease, and whether imbalance of female sexual hormones, responsible for development of female breasts, can lead to manifestation of this disease.
Some researchers state that disturbance of estrogen and progesterone plays an important role in this problem development 9, 10 . Hormonal imbalance may be the consequence of changes in the concentration of steroid receptors and their affi nity for estradiol and progesterone 11 . Under the infl uence of estrogen, interlobular connective tissue collects mucosal edema, which then leads to its swelling and hyalinization. All this dynamics could infl uence the manifestation of mastopathy 
Fig. 3. E2/P ratio in late luteal phase.
E2/P ratio = estradiol/progesterone ratio; MC = menstrual cycle; FBD = fi brocystic breast disease
Fig. 4. Pain and tension during luteal phase in women with fi brocystic breast disease.
and sclero-cystic changes. Estrogen at the breast cell level enhances the synthesis of DNA, mitotic activity, diff erentiation and proliferation of breast cells and connective tissue 12, 13 . What happens with the breast epithelium during the MC secretion phase when a gradual decrease in the estrogen concentration is naturally expected, with a signifi cant rise and maintenance of the progesterone concentration? Th e question is why this sequence is missing even when the lack of progesterone is recorded. While estrogen gives the main impulse to the mammary gland proliferation, the progesterone eff ect is the subject of discussion. Progesterone has a positive, modest or no infl uence, or may even inhibit cell growth. Th e researchers have found that cell proliferation directly depends on the estrogen-progesterone ratio in the breast tissue and that it is lower in the luteal than in the follicular phase 14 . In the breast tissue obtained by aspirate biopsy, it was found that a normal increase of progesterone in the luteal phase resulted in a decrease of the estrogen receptor but not progesterone receptor regulation 15 . Within the normal epithelial cell culture of human breast, researchers have noticed the inhibitory eff ect on cell proliferation due to long-lasting progesterone treatment (7 days) in the presence or absence of estrogen. Also, the cells showed proliferation growth after E2 treatment and returned to the inactive state when P was added 16 . Th e women with high estrogen relative to progesterone (low E2/P ratio) face a higher possibility of developing an atypical benign breast disease with an increased risk of breast cancer 7 . Low endogenous level of luteal progesterone in peri-menopausal women correlates with an increased risk of breast cancer 17 . High level of androgen, either from ovaries or suprarenal glands, showed antagonistic eff ect on progesterone, which infl uenced FBD development, and receptor gene polymorphism, which might result in benign mastopathy and breast cancer 18 . Recent reports show that higher concentrations of medroxyprogesterone acetate (MPA) resulted in the inhibition of proliferation under the infl uence of estrogen.
Rohan et al. tested the eff ect of conjugated equine estrogen (CEE) 0.625 mg/day as a risk for the occurrence of benign proliferative breast disease (BPBD) in the Women's Health Initiative (WHI), a randomized controlled study that included 10,739 women. Th ere were a total of 232 newly diagnosed women with BPBD established during the study (the women were monitored for a mean of 6.9 years). Th e CEE use was connected with a twice higher risk of BPBD (HR-2, 11, 95% CI=1.58-2.81) 19 . Th is led to a conclusion that there was a very important correlation between hyperestrogenemia and etiology of BPBD and that longterm breast exposure to higher estradiol concentration (7 years and more) should be the cause of BPBD development.
Guided by these considerations about E2 level as one of the BPBD causes and knowing that women in reproductive age have the highest estradiol concentration in plasma, we tested our patients exactly during this period of life.
Daily monitoring of E2/P changes during the luteal phase was needed for understanding the FBD pathophysiology. A single sample of E2/P on day 21 was not suffi cient for monitoring its infl uence on the occurrence of cystic breast changes.
Our results showed that in FBD patients, there was a signifi cant decrease in progesterone concentration in plasma on day 24 of MC and increase in estrogen concentration. We postulate that it is just the maintenance of constant hyperestrogenemia and reduced antagonistic anti-proliferation eff ect of the progesterone during the entire late luteal phase of MC that lead to the manifestation of discomfort and clinical fi ndings in the breasts of women with FBD.
We found no correlation between BMI and FBD, which is in line with the report by Friedenreich et al. 8 . All our patients had normal BMI range. On the contrary, Baer et al. found positive correlation between BMI and percentage of BPBD development in the women of reproductive age. Th e women with normal BMI (<25 kg/m 2 ) had by 30% less risk of BPBD 20 . Current knowledge indicates that obesity and excessive body fat represent the grounds for production of higher estradiol and estriol (product of estradiol transformation). Th is means that higher BMI could infl uence (indirectly via hyperestrogenemia) the development of FBD.
To assess the role of prolactin in the pathogenesis of benign breast diseases, Sitruk-Ware et al. measured serum prolactin level before and during the thyrotropin releasing hormone (TRH) test in patients during the luteal phase. Th ey measured serum level of E and P before and during 3 months of treatment with synthetic progesterone, lynestrenol. Th ere was no signifi -cant diff erence in the basic secretion of prolactin before and during therapy, or after TRH injection between patients on therapy and control group 21 . In their study, Walsh et al. found increased prolactin and estradiol concentration in the second half of the luteal phase in women with benign breast disease in comparison with control group 22 . Correlation between prolactin level and FBD could not be found in our study, since all patients had normal prolactin levels.
During the lifespan, every woman sometimes feels cyclic pain, being most expressed in the second phase of MC and related to the increased intake of sweets, coff ee and cigarettes with changes in hormone concentrations 23 . Ayers and Gidwani monitored hormonal changes in the group of women with mastodynia and recorded a signifi cantly lower progesterone in the luteal phase and increased prolactin sensitive to thyrotropin releasing hormone in control group 24 . However, there are other opinions. Th us, in the study that monitored mastalgia in patients 4 to 8 days after ovulation, there was no correlation of dynamic changes with E2/P ratio, hyperprolactinemia and PMS in women with FBD 25 . We consider that it is important to test progesterone concentration in the fi rst or second week after ovulation. Th e low progesterone concentration in the late luteal phase was the cause of mastodynia, mastalgia and PMS in our subjects with FBD.
Conclusion
Normal function of breast cells and tissue depends on an adequate share of estradiol and progesterone concentration. Even the slightest disturbance of the E2/P ratio may contribute to the occurrence of FBD with clinical manifestations of mastalgia and mastodynia, and its correction may improve the quality of life, reduce the frequency of surgical treatments and eventually, the potential risk of developing breast carcinoma.
